Retatrutide peptide results: what the trial data actually shows

Last updated 2026-07-25

What are the actual retatrutide peptide results from clinical trials?

The headline number comes from one study: a phase 2 randomized trial published in the New England Journal of Medicine in 2023. At the highest dose tested, 12 mg weekly by subcutaneous injection, participants lost a mean of 24.2% of body weight by week 48. The placebo group lost 2.1% over the same period ^[1]. That's a roughly 22 percentage point gap, in a trial population of adults with obesity or who were overweight. The trial is registered on ClinicalTrials.gov as NCT04881760, listed under retatrutide's development code LY3437943 ^[2]. That registration is public. Anyone can look up the dose arms, the enrollment criteria, and how the trial was designed. This matters because a lot of what circulates online as "reta peptide results" or "retatrutide peptide before and after" has nothing to do with this data. It's self-reported outcomes from people injecting unregulated material, often at doses nobody has tested. Lower doses in the same trial produced smaller effects, and not everyone hit the 12 mg dose or stayed on it the full 48 weeks. Averages hide a range: some people lost more, some less, and dropout matters for how you read any obesity trial number. Still, a 24.2% mean loss is a big effect size for an incretin drug at this stage of development, larger than what's been reported for semaglutide or tirzepatide in comparable trial windows. Retatrutide has also been studied beyond obesity. There's a registered type 2 diabetes program in addition to the weight trials ^[2], and the drug has moved into later-phase trials, including NCT05929066 and NCT05882045, whose registrations list the comparators and endpoints under study ^{[3] [4]}. That's a broader evidence base than a single headline number, but it's still all pre-approval. Nothing here is a marketed drug yet.

How does retatrutide work differently from semaglutide and tirzepatide?

Retatrutide is a triple agonist. It acts on three receptors at once: GIP, GLP-1, and glucagon ^[1]. Semaglutide (Ozempic, Wegovy) hits only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) hits two, GIP and GLP-1. Retatrutide adds the glucagon receptor on top of that. The theory is that glucagon receptor activity adds energy expenditure on top of appetite suppression, which is part of why the phase 2 weight loss numbers came in higher than earlier incretin trials. That's a mechanistic explanation, not a guarantee it holds up in phase 3, and it doesn't mean the drug is free of tradeoffs. More receptor targets generally means more places for side effects to show up too. For context on lawful, approved incretin options that already exist: semaglutide and tirzepatide are both FDA approved and marketed under those brand names ^[5]. A newer oral option, orforglipron, was approved as Foundayo under NDA 220934, in six strengths from 0.8 mg to 17.2 mg ^[6]. That gives clinicians an approved oral GLP-1 option for patients who might otherwise go looking for investigational compounds online. None of these are triple agonists, so none replicate retatrutide's exact mechanism, but they're real, regulated, and prescribable today.

Is retatrutide FDA approved?

No. A search of Drugs@FDA, the FDA's own database of approved drug products, returns no approved product under the generic name retatrutide ^[5]. It has no brand name, no NDA number, and no approved labeling because it has never cleared an approval review. That means every claim about retatrutide's effects, including the 24.2% figure above, comes from clinical trial data collected under an investigational new drug program, not from a marketed product with an FDA-reviewed label. There is no FDA-set dosing, no approved indication, and no post-market safety surveillance system tracking it the way there is for approved drugs. Anyone telling you retatrutide is "basically approved" or "about to be approved any day" is speculating.

Can a compounding pharmacy legally make retatrutide?

No, and this is worth spelling out because a lot of vendors imply otherwise. Section 503A of the Food, Drug and Cosmetic Act allows compounding pharmacies to use a bulk drug substance only through a specific legal cascade. First, the substance has to comply with an applicable USP or National Formulary monograph, if one exists. If no monograph exists, it has to be a component of an FDA-approved drug. Only if neither of those applies can a pharmacy use a substance from the FDA's 503A Bulks List ^[7]. Retatrutide fails all three steps. There's no USP monograph for it. It's not a component of any FDA-approved drug, because no drug containing retatrutide is approved. And it's not on the 503A Bulks List. The final list contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[8]. No peptide is on that list, and retatrutide isn't one of the six. The separate 503B bulks list, which governs outsourcing facilities rather than individual compounding pharmacies, is its own regulation at 21 CFR 216.24, and it likewise doesn't include retatrutide ^[9]. So there is no version of "compounded retatrutide" that fits inside the current legal framework, whether from a small pharmacy or a large outsourcing facility. FDA also keeps a running public list of substances nominated for the 503A Bulks List, with categories tracking where each nomination stands in the review process ^{[10] [11]}. Retatrutide doesn't appear on that nominations list at all, which means it isn't even in the queue for future consideration right now. In July 2026, FDA's Pharmacy Compounding Advisory Committee met to consider seven different peptides for the bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[12]. Retatrutide wasn't among them and has never been nominated. Even if it had been discussed, a favorable advisory committee vote wouldn't create a compounding pathway by itself. Advisory committee recommendations are non-binding, and actually adding a substance to the list requires full notice-and-comment rulemaking ^[12], a process that takes years, not months.

Separate from the ingredient rules, why can't a pharmacy just source retatrutide as raw material?

Even setting aside the three-step ingredient cascade, section 503A has an independent requirement: the bulk drug substance has to come from an establishment registered under section 510 of the FD&C Act, and it has to come with a valid certificate of analysis ^[7]. Research-use-only material bought from an unregistered supplier fails this requirement no matter what else is true about the ingredient itself. This is the part that gray-market vendors tend to skip over. A lot of "retatrutide peptide" sold online is labeled research use only, not for human consumption. That disclaimer doesn't establish legality on its own, and it definitely doesn't establish that the material was made in a registered, inspected facility with a real certificate of analysis behind it. You have no way to verify purity, concentration, or sterility from a research-labeled vial, and no pharmacy compounding it that way would be operating inside section 503A even if retatrutide somehow made it onto the bulks list tomorrow.

Does a research-use-only label make retatrutide legal to sell?

No. FDA has been direct about this. Intended use isn't decided by the label alone, it's grounded in labeling claims, advertising, and statements made by the seller, under 21 CFR 201.128 ^[13]. If a company's marketing describes weight loss, fat reduction, or other therapeutic effects, that marketing establishes the product's intended use as a drug, disclaimer or not. FDA acted on exactly this reasoning in a March 2026 warning letter to Gram Peptides. The agency wrote that despite research-use-only and not-for-human-consumption labeling, "evidence from the company's website established that its products were intended to be drugs for human use," and the letter specifically named retatrutide as one of the products marketed on that site ^[14]. That's a real, cited example of FDA applying this standard to a retatrutide seller, not a hypothetical. The practical upshot: if you see a vendor's site describing weight loss outcomes, before-and-after language, or dosing advice for retatrutide, the research-use disclaimer sitting at the bottom of the page does essentially nothing to change the product's legal status. It's marketed as a drug because it's described as one.

What about retatrutide peptide Reddit results and anecdotal reports?

You'll find plenty of posts describing dramatic weight loss from self-sourced retatrutide, along with side effect reports, dosing schedules, and photos. None of it is verifiable. There's no way to confirm what was actually in the vial, what the real concentration was, whether it was sterile, or whether the person reporting results was accurately tracking dose and diet. This isn't a knock on any individual poster. It's a structural problem. Clinical trials work specifically because they have known, verified drug product, blinded comparison groups, and standardized measurement. Reddit threads have none of that. A post claiming someone lost 20 pounds in six weeks on unregulated "reta peptide" tells you nothing reliable about dose-response, safety, or even whether retatrutide was in the product at all. Contamination, mislabeling, and wildly variable actual concentration are documented problems across the gray-market peptide supply chain generally, and there's no registered-facility certificate of analysis behind most of what's sold this way ^[7]. If you want a real read on retatrutide peptide results, the ClinicalTrials.gov registrations and the NEJM publication are the only sources with methodology you can actually check ^{[1] [2]}.

What doses were used in the retatrutide trials, and does that mean it's safe to self-administer?

The phase 2 obesity trial dosed participants weekly by subcutaneous injection, with dose arms up to 12 mg, and the 24.2% weight loss figure at 48 weeks corresponds specifically to that top dose ^{[1] [2]}. That's what the trial protocol specifies, and it's public information anyone can verify on the registration. It is not a recommendation, and no clinician can lawfully prescribe retatrutide to you outside an active clinical trial, because there is no approved product and no compounding pathway that reaches it, as covered above ^{[5] [7] [8]}. Trial dosing happened under close medical supervision, with lab monitoring, safety visits, and a defined protocol for adjusting or stopping the drug. None of that infrastructure exists if you're self-injecting research-labeled material at home based on a forum post. If you're looking at retatrutide dosage chart content or retatrutide dosage calculator tools online, understand that those are describing trial data, not a prescribable protocol you can act on outside a study.

Why can't I obtain retatrutide from an online vendor or by importing it myself?

Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application ^[15]. Retatrutide has no approved application, so it cannot legally be sold as a drug in the US under any circumstance right now, vendor disclaimers aside. Some people look at personal importation as a workaround. FDA does publish a personal importation policy, but it's narrow, and it generally applies to limited situations (like an approved drug not available domestically for a serious condition, in small quantities, for personal use) ^[16]. It was never designed to cover investigational compounds with no approval anywhere, and retatrutide doesn't fit the policy's intent. Ordering it from an overseas source doesn't create legal cover just because the shipment crosses a border. See retatrutide peptide buy for a fuller breakdown of why purchase attempts don't have a lawful path right now.

What are the real, lawful options for someone considering retatrutide right now?

If you're drawn to retatrutide because of the phase 2 numbers, the honest answer is: you can't get the actual studied drug outside a clinical trial, and trial enrollment is the only way to access real retatrutide under medical supervision. Check ClinicalTrials.gov listings like NCT05929066 and NCT05882045 for whether recruitment is open near you and whether you meet the criteria ^{[3] [4]}. Outside of a trial, the lawful, approved incretin options are semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and now orforglipron (Foundayo) ^{[6] [5]}. These have FDA-reviewed labeling, established safety monitoring, and a physician can actually prescribe them with legal certainty. None of them is a triple agonist, so none will fully replicate retatrutide's trial numbers, but they're real drugs with real data behind them today, not a research-labeled vial of unknown origin. NIDDK, the federal government's diabetes and digestive disease research institute, publishes general guidance on evidence-based weight management approaches that's worth reading as a neutral starting point while you wait on the trial data to mature . If retatrutide does eventually get approved, that pathway runs through FDA review, not through a supplement store or an overseas peptide vendor. Retatrutide Report tracks that approval timeline as it develops, alongside the trial results as later-phase data reads out.

What should I know before trusting any "retatrutide peptide before and after" photo or claim?

Treat any before-and-after image from an unverified source the same way you'd treat an ad: interesting, not evidence. Ask what was actually injected, at what dose, for how long, and whether diet or other drugs were involved. None of that is answerable for gray-market claims. The only results with real methodology behind them are the phase 2 NEJM trial (24.2% mean weight loss at 12 mg, 48 weeks, versus 2.1% placebo) ^[1] and the ongoing registered trials tracking longer-term and diabetes-specific outcomes ^{[2] [3] [4]}. Everything else, including most "reta peptide results" content online, is anecdotal and unverifiable, often from products with no certificate of analysis and no registered manufacturing behind them ^[7]. That gap between trial evidence and internet anecdote is the single most important thing to understand before you read further into this drug.

Frequently asked questions

What percentage of weight loss did retatrutide show in trials?

In the phase 2 obesity trial, the 12 mg weekly dose produced a mean 24.2% weight reduction at 48 weeks, compared to 2.1% for placebo (Jastreboff et al., NEJM, 2023). Lower doses in the same trial produced smaller effects. This is the only large, controlled dataset on retatrutide's weight loss effect currently published.

Is retatrutide the same as tirzepatide or semaglutide?

No. Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors. Tirzepatide (Mounjaro, Zepbound) hits GIP and GLP-1. Semaglutide (Ozempic, Wegovy) hits only GLP-1. All three are incretin-based drugs, but retatrutide's third target is thought to add extra energy expenditure on top of appetite suppression.

Is there a legal way to obtain retatrutide peptide online?

No lawful path exists. Retatrutide has no FDA approval, isn't on the 503A or 503B compounding bulks lists, and can't be introduced into interstate commerce as a drug under 21 U.S.C. 355. Vendor research-use-only disclaimers don't change this if the site's marketing describes therapeutic effects, per FDA's own intended-use standard.

Why isn't retatrutide on the FDA's compounding bulks list?

The 503A Bulks List contains exactly six substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, thymol iodide), none of them peptides. Retatrutide has never been nominated for it, has no USP monograph, and isn't a component of any approved drug, so it fails every step of the compounding cascade under 503A.

Does a research-use-only label make retatrutide peptide sales legal?

No. FDA's regulation on intended use (21 CFR 201.128) says labeling claims, advertising, and seller statements establish a product's intended use, not the disclaimer. FDA cited this reasoning in a March 2026 warning letter against a retatrutide seller, finding the site's marketing established the product as an intended drug despite a research-use label.

Are Reddit reports of retatrutide peptide results reliable?

Not in any verifiable way. Self-reported forum results come from unregulated material with no certificate of analysis, no confirmed concentration, and no controlled comparison group. Clinical trial data (NEJM 2023, ClinicalTrials.gov NCT04881760) is the only source with confirmed dosing and independent oversight behind the numbers.

What dose of retatrutide was used to get 24% weight loss?

The 24.2% mean weight loss at 48 weeks came from the highest studied dose, 12 mg weekly by subcutaneous injection, in the phase 2 trial. This is trial-protocol dosing under medical supervision, reported for informational purposes; no clinician can currently prescribe this dose, or any dose, outside an active clinical trial.

Is there an FDA-approved alternative to retatrutide right now?

Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both FDA-approved incretin drugs. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo (NDA 220934) in strengths from 0.8 mg to 17.2 mg. None matches retatrutide's triple-receptor mechanism, but all are lawfully prescribable with FDA-reviewed safety data.

Could retatrutide get FDA approved soon?

It's in later-phase trials (NCT05929066, NCT05882045) beyond the phase 2 obesity study, and also has a registered type 2 diabetes program, but there's no approved application yet. Drugs@FDA shows no approved product under the name retatrutide. No public timeline for an approval decision has been established.

What happened with FDA and Gram Peptides selling retatrutide?

In a March 2026 warning letter (MARCS-CMS 721806), FDA found that despite research-use-only and not-for-human-consumption labeling, the company's website marketing established its products, including retatrutide, as intended for human drug use. This is a documented example of FDA enforcement against a specific retatrutide seller.

Can a doctor prescribe retatrutide off-label?

No. Off-label prescribing applies to FDA-approved drugs used outside their approved indication. Retatrutide has no FDA approval for any indication, so there's no approved product for a doctor to prescribe off-label. Access is currently limited to enrollment in a registered clinical trial.

What's the difference between the 503A and 503B compounding lists?

503A governs traditional compounding pharmacies; 503B governs larger outsourcing facilities. Both maintain separate bulk drug substance lists (21 CFR 216.23 for 503A's six-substance final list, 21 CFR 216.24 for 503B). Retatrutide appears on neither list, so neither type of compounder can lawfully use it as an ingredient.

Is personal importation of retatrutide legal under FDA policy?

FDA's personal importation policy is narrow and generally intended for approved drugs unavailable domestically, in small quantities, for serious conditions. Retatrutide is an unapproved investigational drug, so it doesn't fit the policy's intent, and importing it doesn't create legal cover simply because it crosses an international border.

Sources

1. Jastreboff AM et al., New England Journal of Medicine, 2023: Phase 2 trial: 24.2% mean weight loss at 12 mg retatrutide vs 2.1% placebo at 48 weeks; retatrutide is a GIP/GLP-1/glucagon triple agonist.
2. ClinicalTrials.gov NCT04881760: Registration for the phase 2 retatrutide (LY3437943) obesity trial, listing dose arms, comparators, and that a type 2 diabetes program also exists.
3. ClinicalTrials.gov NCT05929066: Later-phase retatrutide trial registration listing enrollment criteria, comparators and endpoints.
4. ClinicalTrials.gov NCT05882045: Second later-phase retatrutide trial registration, an independent record of dosing and design.
5. Drugs@FDA, FDA-approved drug products database: A search for retatrutide returns no FDA-approved product.
6. 21 U.S.C. 353a(b)(1)(A)(i), Cornell Law: Section 503A compounding cascade requiring a USP/NF monograph, then FDA-approved drug component, then bulks list, in that order.
7. 21 CFR 216.23, eCFR: The final 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them.
8. 21 CFR 216.24, eCFR: The separate 503B bulks list for outsourcing facilities also does not include retatrutide.
9. Drugs@FDA, NDA 220934: Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg.
10. Federal Register, Docket FDA-2025-N-6895: FDA's Pharmacy Compounding Advisory Committee considered seven peptides for the bulks list in July 2026, not including retatrutide; advisory votes are non-binding and adding a substance requires notice-and-comment rulemaking.
11. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public list of 503A bulk substances by interim category does not include retatrutide.
12. FDA, Bulk Drug Substances Nominated for Use in Compounding (PDF): The nominations document records Category 1, 2, and 3 rosters; retatrutide has never been nominated.
13. 21 CFR 201.128, eCFR: Intended use is grounded in labeling claims, advertising, and seller statements, not disclaimers.
14. 21 U.S.C. 355, Cornell Law: A new drug cannot be introduced into interstate commerce without an approved application.
15. FDA, Personal Importation: FDA's personal importation policy and its narrow scope, which does not cover unapproved investigational drugs like retatrutide.
16. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference point.